Efficacy News and Research

RSS

Protein helps leukemia cells avoid effects of chemotherapy by appearing dormant

A new study on how the progression of acute lymphocytic leukemia is influenced by the bone marrow environment has demonstrated for the first time that targeting a specialized protein known as osteopontin may be an effective strategy to increase the efficacy of chemotherapy in patients with this type of blood cancer.

16 Apr 2013

Frozen balls of ice can safely kill cancerous tumors in lungs

Frozen balls of ice can safely kill cancerous tumors that have spread to the lungs, according to the first prospective multicenter trial of cryoablation. The results are being presented at the Society of Interventional Radiology's 38th Annual Scientific Meeting in New Orleans.

15 Apr 2013

KYTHERA Biopharmaceuticals reports positive results from Phase IIb study of ATX-101

KYTHERA Biopharmaceuticals, Inc. today presented positive results that found MRI measurements of patients treated with ATX-101 demonstrated a statistically significant reduction in submental fat, commonly known as double chin, during an oral session at The Aesthetic Meeting 2013, organized by the American Society for Aesthetic Plastic Surgery, April 11-16, New York, NY.

15 Apr 2013

Nalmefene can provide important clinical benefit for alcohol-dependent patients

A potential new treatment for alcoholism called nalmefene is effective and safe for reducing alcohol consumption in alcohol dependent individuals, says a new study published this week in Biological Psychiatry.

12 Apr 2013

ATSP-9172 exhibits on-target binding activity in human prostate cancer model

Aileron Therapeutics, Inc. today announced new preclinical data demonstrating that ATSP-9172, its Stapled Peptide inhibitor of HIF-1α-dependent transcription, exhibits on-target binding activity, favorable pharmacokinetic properties and potent in vivo efficacy in a human prostate cancer model.

12 Apr 2013

Sorbent Therapeutics starts patient dosing in Phase 2b clinical trial of CLP-1001

Sorbent Therapeutics, Inc., a biopharmaceutical company developing therapies for cardiovascular and renal diseases, today announced that patient dosing has commenced in its Phase 2b clinical trial of CLP-1001.

12 Apr 2013

Cellectis CanCELL cell lines enable drug positioning in cancer pathways

CanCELL cell lines are featuring gene knock-outs of the major cancer relevant oncogenes and tumor suppressor genes. This new product line answers identified market needs in oncology research and drug discovery.

11 Apr 2013

German researchers evaluate short-term cognitive pain management techniques for acute pain

Those who accept their pain condition are best able to tolerate pain, while distraction can be the way to lower pain intensity, according to research reported in The Journal of Pain, the peer review publication of the American Pain Society.

11 Apr 2013

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced today that two analyses of VICTRELIS (boceprevir) and data from Phase II studies of two of Merck's investigational medicines for chronic hepatitis C virus (HCV) genotype 1, MK-5172 and vaniprevir (MK-7009), will be presented at the 2013 International Liver Congress (EASL) Annual Meeting.

11 Apr 2013

New data on use of PBD dimers as warheads in ADCs presented at AACR annual meeting

Spirogen, a leading oncology-focused company developing DNA sequence targeted agents, and BioAtla LLC, a San Diego headquartered antibody therapeutics developer, today announced new data on the use of pyrrolobenzodiazepine (PBD) dimers as warheads in antibody drug conjugates (ADCs) at the annual meeting of the American Association for Cancer Research (AACR) in Washington, DC.

11 Apr 2013

BioLineRx gets regulatory approvals in US to start BL-8040 Phase IIa trial for treatment of AML

BioLineRx, a biopharmaceutical development company, announced today that it has received all necessary regulatory approvals in the US to commence a Phase IIa trial for BL-8040, for the treatment of Acute Myeloid Leukemia.

11 Apr 2013

ImmunoGen discloses preclinical data for EGFR-targeting ADC, IMGN289

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer therapeutics using its Targeted Antibody Payload technology, disclosed for the first time today preclinical data for its EGFR-targeting ADC, IMGN289.

11 Apr 2013

Data on PV-10 combination therapy presented at AACR Annual Meeting

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, presented data on PV-10 combination therapy today at the American Association for Cancer Research Annual Meeting in Washington, DC.

11 Apr 2013

Scientists demonstrate feasibility of using already-approved drugs against pathogens

In the most extensive screen of its kind, Texas Biomed scientists in San Antonio have demonstrated the feasibility of repurposing already-approved drugs for use against highly pathogenic bacteria and viruses.

11 Apr 2013

Tiny proteins prevent bacterial gene transcription

In the search for new antibiotics, researchers are taking an unusual approach: They are developing peptides, short chains of protein building blocks that effectively inhibit a key enzyme of bacterial metabolism.

10 Apr 2013

CYP1B1 protein prevents head and neck cancers, say researchers

Head and neck cancers typically begin in squamous cells that line moist surfaces inside the mouth, nose and throat. Squamous cell carcinoma of the head and neck (HNSCC) is the sixth most common type of cancer in the United States, and it is sometimes preceded by the appearance of changes inside the oral cavity called precancerous lesions.

10 Apr 2013

Galectin Therapeutics provides details on first-in-man Phase 1 clinical trial of GR-MD-02

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced details today on its first-in-man Phase 1 clinical trial that will support a proposed indication of GR-MD-02 for treatment of non-alcoholic steatohepatitis (NASH, or fatty liver disease) with advanced fibrosis.

10 Apr 2013

Olympus receives FDA clearance for Articulating HD 3D Laparoscopic Surgical Video System

Olympus, a precision technology leader in designing and delivering innovative solutions in Medical and Surgical Products, among other core businesses, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration for its Articulating HD 3D Laparoscopic Surgical Video System.

From Evident Corporation - Life Sciences 10 Apr 2013

REFRESH study: RP5063 shows promise for schizophrenia and schizoaffective disorder

Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.

10 Apr 2013

CvergenX to develop radiosensitivity test to better radiation therapy decisions for patients with cancer

A molecular signature index technology that can lead to better radiation therapy decisions for patients with cancer is being developed into a reliable radiosensitivity test by CvergenX, Inc., an advanced cancer diagnostics company.

10 Apr 2013

Efficacy News and Research

Protein helps leukemia cells avoid effects of chemotherapy by appearing dormant

Frozen balls of ice can safely kill cancerous tumors in lungs

KYTHERA Biopharmaceuticals reports positive results from Phase IIb study of ATX-101

Nalmefene can provide important clinical benefit for alcohol-dependent patients

ATSP-9172 exhibits on-target binding activity in human prostate cancer model

Sorbent Therapeutics starts patient dosing in Phase 2b clinical trial of CLP-1001

Cellectis CanCELL cell lines enable drug positioning in cancer pathways

German researchers evaluate short-term cognitive pain management techniques for acute pain

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

New data on use of PBD dimers as warheads in ADCs presented at AACR annual meeting

BioLineRx gets regulatory approvals in US to start BL-8040 Phase IIa trial for treatment of AML

ImmunoGen discloses preclinical data for EGFR-targeting ADC, IMGN289

Data on PV-10 combination therapy presented at AACR Annual Meeting

Scientists demonstrate feasibility of using already-approved drugs against pathogens

Tiny proteins prevent bacterial gene transcription

CYP1B1 protein prevents head and neck cancers, say researchers

Galectin Therapeutics provides details on first-in-man Phase 1 clinical trial of GR-MD-02

Olympus receives FDA clearance for Articulating HD 3D Laparoscopic Surgical Video System

REFRESH study: RP5063 shows promise for schizophrenia and schizoaffective disorder

CvergenX to develop radiosensitivity test to better radiation therapy decisions for patients with cancer

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News